Company Profile

DR. REDDYS LABORATORIES LTD.

NSE : DRREDDYBSE : 500124ISIN CODE : INE089A01023Industry : Pharmaceuticals & DrugsHouse : Dr. Reddy's
BSE3822.85-70.25 (-1.8 % )
PREV CLOSE (Rs.) 3893.10
OPEN PRICE (Rs.) 3893.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 37317
TODAY'S LOW / HIGH (Rs.)3815.80 3918.00
52 WK LOW / HIGH (Rs.)2352 4189.35
NSE3823.50 -68.5 (-1.76 % )
PREV CLOSE(Rs.) 3892.00
OPEN PRICE (Rs.) 3894.90
BID PRICE (QTY) 3823.50 (164 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 1035997
TODAY'S LOW / HIGH(Rs.) 3814.00 3919.00
52 WK LOW / HIGH (Rs.)2351.2 4190

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.01
Dividend Yield(%) 0.65
TTM EPS (Rs.) 176.72
P/E Ratio 21.63
Book Value (Rs.) 907.65
Face Value (Rs.) 5
MCap (Rs. in Mn) 635481.97
Price/Earning (TTM) 17.05
Price/Sales (TTM) 5.36
Price/Book (MRQ) 4.21
PAT Margin (%) 24.79
ROCE (%) 18.58
Incorporation Year : 1984

Management Info :

K Satish Reddy - Chairman GV Prasad - Managing Director

Registered Office :

Address : 8-2-337,Road No. 3,Banjara Hills,
Hyderabad,
Telangana-500034

Phone : 040 - 4900 2900

Website : www.drreddys.com

Registrar's Details : Bigshare Services Pvt Ltd
306, Right Wing, Amrutha Ville, Opp. Yasodha Hospital,Raj Bhavan Road,Somajiguda,Hyderabad
Listing : BSE, NSE, MCX, New York
NEWS More
06Jul07-06-2020$Dr. Reddy's expecting overall performance to be quite volatile in current fiscal Dr. Reddy's expecting overal
Dr. Reddy's Laboratories is expecting its overall performance to be quite volatile in the current fiscal with uncertainties related to COVID-19 set to increase during the period. As per the company, overall, there was no major impact of the pandemic during the last fiscal, including the fourth quarter.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
Dr. Reddy's Laboratories is expecting its overall performance t..
02Jul07-02-2020$Dr. Reddys Laboratories gains as its inks pact with FUJIFILM, Global Response Aid Dr. Reddys Laboratories gain

Dr. Reddys Laboratories is currently trading at Rs. 3916.95, up by 6.35 points or 0.16% from its previous closing of Rs. 3910.60 on the BSE.

The scrip opened at Rs. 3959.00 and has touched a high and low of Rs. 3977.00 and Rs. 3902.00 respectively. So far 13012 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4189.35 on 10-Jun-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.

Last one week high and low of the scrip stood at Rs. 4064.65 and Rs. 3887.00 respectively. The current market cap of the company is Rs. 65118.26 crore.

The promoters holding in the company stood at 26.75%, while Institutions and Non-Institutions held 44.50% and 14.65% respectively.

Dr Reddy's Laboratories has partnered with FUJIFILM Corporation through FUJIFILM Toyama Chemical (FUJIFILM) and Global Response Aid (GRA) for the development, manufacture and sales of Avigan Tablets (generic name: favipiravir), a potential treatment of COVID-19. 

Under the tripartite agreement signed on June 30, 2020, FUJIFILM grants Dr. Reddy’s the exclusive rights of manufacturing and also grants both Dr. Reddy’s and GRA the rights to develop, sell and distribute Avigan in all countries other than Japan, China and Russia. The company would have exclusive rights for development, selling and distribution of Avigan in India. Further, FUJIFILM would receive an upfront license fee and royalties on sales from Dr. Reddy’s and GRA. The FUJIFILM Group is currently conducting a clinical study on Avigan targeting COVID-19 patients in Japan and the US, and is working to increase the drug’s production by partnering with domestic and overseas companies. Dr. Reddy’s and GRA shall introduce the product in the market post all applicable approvals in the respective countries.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.



Dr. Reddys Laboratories is currently trading at Rs. 3916.95, up..
01Jul07-01-2020$Dr Reddy's Laboratories inks pact with FUJIFILM, Global Response Aid Dr Reddy's Laboratories inks
Dr Reddy's Laboratories has partnered with FUJIFILM Corporation through FUJIFILM Toyama Chemical (FUJIFILM) and Global Response Aid (GRA) for the development, manufacture and sales of Avigan Tablets (generic name: favipiravir), a potential treatment of COVID-19. 
 
Under the tripartite agreement signed on June 30, 2020, FUJIFILM grants Dr. Reddy’s the exclusive rights of manufacturing and also grants both Dr. Reddy’s and GRA the rights to develop, sell and distribute Avigan in all countries other than Japan, China and Russia. The company would have exclusive rights for development, selling and distribution of Avigan in India. Further, FUJIFILM would receive an upfront license fee and royalties on sales from Dr. Reddy’s and GRA. The FUJIFILM Group is currently conducting a clinical study on Avigan targeting COVID-19 patients in Japan and the US, and is working to increase the drug’s production by partnering with domestic and overseas companies. Dr. Reddy’s and GRA shall introduce the product in the market post all applicable approvals in the respective countries.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr Reddy's Laboratories has partnered with FUJIFILM Corporation..
29Jun06-29-2020$Dr Reddy's expects to launch 25 products in US market in FY21 Dr Reddy's expects to launch

Dr Reddy's Laboratories is expecting to launch 25 products in the US market in the current financial year (FY21). The drug major has also earmarked a capital expenditure (capex) of Rs 1,000 crore for finding various projects during the ongoing financial year.

Besides, the drug maker is also working on various biosimilar products, including, the Rituximab Phase III trial is progressing as per plan. And, in parallel, it is working on multiple other biosimilar products, which are at different stage of development.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr Reddy's Laboratories is expecting to launch 25 products in t..
29Jun06-29-2020$ITI, Mahindra Logistics and Coal India to see some action today ITI, Mahindra Logistics and

ITI and Tech Mahindra have signed a Memorandum of Understanding (MoU) to work together in the areas of 4G & 5G smart networks, Smart Cities and Health Care services, in order to supplement country's requirement of self-reliance in the area of Telecommunication. ITI and Tech Mahindra will collaborate to create ‘Make in India’ stack as part of this MoU for the upcoming 4G & 5G opportunities in India.

Mahindra Logistics’ board has approved further investment in Lords Freight (India), subsidiary company by way of purchase of 3,80,970 equity shares of Lords (representing 16.13% of equity share capital of Lords) from the existing promoter shareholders of Lords. Presently, the company holds 82.92% of the share capital of Lords and on completion of the transfer formalities of said 3,80,970 equity shares of Lords, the company's shareholding in Lords would increase by 16.13%. The Investment Committee of the Board of Directors of the company at their Meeting held on June 27, 2020, has approved the same.

Coal India’s subsidiary -- Northern Coalfields (NCL) is looking to pump in Rs 7,000 crore over the next four years to ramp up production capacity and boost infrastructure at various projects. Of this amount, an investment of about Rs 3,000 crore is planned for procurement of heavy earthmoving machines and another Rs 3,000 crore will be used for development of additional coal evacuation-related infrastructure. Around Rs 200 crore will be used in developing 50 MW solar power plant.

Adani Green Energy has received shareholders' approval to raise Rs 2,500 crore in its fifth annual general meeting held on June 25, 2020. The company also got shareholders’ nod to have flexibility to infuse additional capital to tap capital markets and to raise additional long term resources, if necessary, in order to sustain rapid growth in the business, for business expansion and to improve the financial leveraging strength of the firm.

Dr Reddy's Laboratories is expecting to launch 25 products in the US market in the current financial year (FY21). The drug major has also earmarked a capital expenditure (capex) of Rs 1,000 crore for finding various projects during the ongoing financial year. Besides, the drug maker is also working on various biosimilar products, including, the Rituximab Phase III trial is progressing as per plan. And, in parallel, it is working on multiple other biosimilar products, which are at different stage of development.

CA Clover Intermediate II Investments, an affiliated entity of CAP V Mauritius, an investment fund managed and advised by affiliated entities of The Carlyle Group Inc. has agreed to invest fresh equity capital for a 20% stake in Piramal Enterprises’ wholly owned subsidiary -- Piramal Pharma. The estimated equity capital investment in Piramal Pharma would amount to over Rs 3,700 crore. The final amount of equity investment will depend on the net debt, exchange rate and performance against the pre-agreed conditions at the time of closing of the deal.

IDBI bank has received an approval to sell its stake held in IDBI Federal Life Insurance Company (IFLI) to the extent of 23% to Ageas and 4% to Federal Bank at a combined value of about Rs 595 crore. The meeting of Board of Directors of the bank held on June 26, 2020, approved the same.

ITI and Tech Mahindra have signed a Memorandum of Understanding..
Financials More
Rs. in Millions
QTR Mar 20 ANNUAL 20
Net Profit502829377
Gross Profit 4441 27758
Operating Profit 648236128
Net Sales 28517118504
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 15799.85 (0.44%)
M.Cap ( in Cr)
33573.58
Jenburkt Pharma (BSE)
 399.40 (8.56%)
M.Cap ( in Cr)
183.30
Alembic Pharma (BSE)
 915.00 (3.15%)
M.Cap ( in Cr)
17249.21
Divis Lab (BSE)
 2183.80 (1.04%)
M.Cap ( in Cr)
57973.03
Themis Medicare (BSE)
 354.75 (4.34%)
M.Cap ( in Cr)
325.94
Shareholding Pattern More
MUTUAL FUNDS/UTI 8.75 %
FI/BANKS/INSURANCE 5.49 %
PROMOTERS 26.75 %
NON-INSTITUTION 14.65 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes